207 related articles for article (PubMed ID: 26472049)
1. The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy.
Zhang G; Guo D; Dash PK; Araínga M; Wiederin JL; Haverland NA; Knibbe-Hollinger J; Martinez-Skinner A; Ciborowski P; Goodfellow VS; Wysocki TA; Wysocki BJ; Poluektova LY; Liu XM; McMillan JM; Gorantla S; Gelbard HA; Gendelman HE
Nanomedicine; 2016 Jan; 12(1):109-22. PubMed ID: 26472049
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice.
Puligujja P; Araínga M; Dash P; Palandri D; Mosley RL; Gorantla S; Poluektova L; McMillan J; Gendelman HE
Antiviral Res; 2015 Aug; 120():85-8. PubMed ID: 26026666
[TBL] [Abstract][Full Text] [Related]
3. Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.
Guo D; Zhang G; Wysocki TA; Wysocki BJ; Gelbard HA; Liu XM; McMillan JM; Gendelman HE
J Virol; 2014 Sep; 88(17):9504-13. PubMed ID: 24920821
[TBL] [Abstract][Full Text] [Related]
4. Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs.
Gnanadhas DP; Dash PK; Sillman B; Bade AN; Lin Z; Palandri DL; Gautam N; Alnouti Y; Gelbard HA; McMillan J; Mosley RL; Edagwa B; Gendelman HE; Gorantla S
J Clin Invest; 2017 Mar; 127(3):857-873. PubMed ID: 28134625
[TBL] [Abstract][Full Text] [Related]
5. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.
Dash PK; Gendelman HE; Roy U; Balkundi S; Alnouti Y; Mosley RL; Gelbard HA; McMillan J; Gorantla S; Poluektova LY
AIDS; 2012 Nov; 26(17):2135-44. PubMed ID: 22824628
[TBL] [Abstract][Full Text] [Related]
6. Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages.
Araínga M; Guo D; Wiederin J; Ciborowski P; McMillan J; Gendelman HE
Retrovirology; 2015 Jan; 12():5. PubMed ID: 25608975
[TBL] [Abstract][Full Text] [Related]
7. Modulating cellular autophagy for controlled antiretroviral drug release.
Thomas MB; Gnanadhas DP; Dash PK; Machhi J; Lin Z; McMillan J; Edagwa B; Gelbard H; Gendelman HE; Gorantla S
Nanomedicine (Lond); 2018 Sep; 13(17):2139-2154. PubMed ID: 30129397
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.
Puligujja P; Balkundi SS; Kendrick LM; Baldridge HM; Hilaire JR; Bade AN; Dash PK; Zhang G; Poluektova LY; Gorantla S; Liu XM; Ying T; Feng Y; Wang Y; Dimitrov DS; McMillan JM; Gendelman HE
Biomaterials; 2015 Feb; 41():141-50. PubMed ID: 25522973
[TBL] [Abstract][Full Text] [Related]
9. Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy.
Martinez-Skinner AL; Araínga MA; Puligujja P; Palandri DL; Baldridge HM; Edagwa BJ; McMillan JM; Mosley RL; Gendelman HE
PLoS One; 2015; 10(12):e0145966. PubMed ID: 26716700
[TBL] [Abstract][Full Text] [Related]
10. Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections.
Puligujja P; McMillan J; Kendrick L; Li T; Balkundi S; Smith N; Veerubhotla RS; Edagwa BJ; Kabanov AV; Bronich T; Gendelman HE; Liu XM
Nanomedicine; 2013 Nov; 9(8):1263-73. PubMed ID: 23680933
[TBL] [Abstract][Full Text] [Related]
11. The new small-molecule mixed-lineage kinase 3 inhibitor URMC-099 is neuroprotective and anti-inflammatory in models of human immunodeficiency virus-associated neurocognitive disorders.
Marker DF; Tremblay MÈ; Puccini JM; Barbieri J; Gantz Marker MA; Loweth CJ; Muly EC; Lu SM; Goodfellow VS; Dewhurst S; Gelbard HA
J Neurosci; 2013 Jun; 33(24):9998-10010. PubMed ID: 23761895
[TBL] [Abstract][Full Text] [Related]
12. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
[TBL] [Abstract][Full Text] [Related]
13. Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.
Kanmogne GD; Singh S; Roy U; Liu X; McMillan J; Gorantla S; Balkundi S; Smith N; Alnouti Y; Gautam N; Zhou Y; Poluektova L; Kabanov A; Bronich T; Gendelman HE
Int J Nanomedicine; 2012; 7():2373-88. PubMed ID: 22661891
[TBL] [Abstract][Full Text] [Related]
14. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Le Tiec C; Barrail A; Goujard C; Taburet AM
Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
[TBL] [Abstract][Full Text] [Related]
16. Broad Spectrum Mixed Lineage Kinase Type 3 Inhibition and HIV-1 Persistence in Macrophages.
Saminathan P; Kevadiya BD; Marker DF; Gendelman HE; Gorantla S; Gelbard HA
J Neuroimmune Pharmacol; 2019 Mar; 14(1):44-51. PubMed ID: 30617749
[TBL] [Abstract][Full Text] [Related]
17. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial.
Bunupuradah T; Kiertiburanakul S; Avihingsanon A; Chetchotisakd P; Techapornroong M; Leerattanapetch N; Kantipong P; Bowonwatanuwong C; Banchongkit S; Klinbuayaem V; Mekviwattanawong S; Nimitvilai S; Jirajariyavej S; Prasithsirikul W; Munsakul W; Bhakeecheep S; Chaivooth S; Phanuphak P; Cooper DA; Apornpong T; Kerr SJ; Emery S; Ruxrungtham K;
Lancet HIV; 2016 Aug; 3(8):e343-e350. PubMed ID: 27470026
[TBL] [Abstract][Full Text] [Related]
18. Atazanavir/ritonavir: a review of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
[TBL] [Abstract][Full Text] [Related]
19. Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient.
Lanzafame M; Lattuada E; Nicolè S; Rigo F; Cucchetto G; Concia E; Vento S
Int J STD AIDS; 2017 Jun; 28(7):726-728. PubMed ID: 27789848
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations.
Gautam N; Puligujja P; Balkundi S; Thakare R; Liu XM; Fox HS; McMillan J; Gendelman HE; Alnouti Y
Antimicrob Agents Chemother; 2014 Dec; 58(12):7510-9. PubMed ID: 25288084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]